NCT03733717View on ClinicalTrials.gov

Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 22, 2018

Primary Completion Date

September 6, 2020

Study Completion Date

August 25, 2023

Conditions
Multiple Myeloma
Interventions
DRUG

Isatuximab SAR650984

"Pharmaceutical form: Concentrate for solution~Route of administration: Intravenous"

Trial Locations (3)

100191

Investigational Site Number 1560003, Beijing

210029

Investigational Site Number 1560002, Nanjing

300020

Investigational Site Number 1560001, Tianjin

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY